Another study with erlotinib (150 mg OD) in 42 EFGR-mutation NSCLC patients demonstrated an ORR of 30.6% overall; 32.1% in EGFR+ and 62.5% in MET-advanced subgroup, along with a median PFS of 5.9 months and disease-control rates (DCR) of 86.1% in EGFR+ and 100% in MET-advanced subgroup (41). The gene discussed is EGFR; the disease is non-small cell lung carcinoma.